These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28685225)

  • 1. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
    Jasim S; Suman VJ; Jimenez C; Harris P; Sideras K; Burton JK; Worden FP; Auchus RJ; Bible KC
    Endocrine; 2017 Aug; 57(2):220-225. PubMed ID: 28685225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
    Bible KC; Suman VJ; Molina JR; Smallridge RC; Maples WJ; Menefee ME; Rubin J; Karlin N; Sideras K; Morris JC; McIver B; Hay I; Fatourechi V; Burton JK; Webster KP; Bieber C; Traynor AM; Flynn PJ; Cher Goh B; Isham CR; Harris P; Erlichman C;
    J Clin Endocrinol Metab; 2014 May; 99(5):1687-93. PubMed ID: 24606083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
    Pili R; Qin R; Flynn PJ; Picus J; Millward M; Ho WM; Pitot H; Tan W; Miles KM; Erlichman C; Vaishampayan U
    Clin Genitourin Cancer; 2013 Dec; 11(4):477-83. PubMed ID: 23891158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
    Bible KC; Suman VJ; Molina JR; Smallridge RC; Maples WJ; Menefee ME; Rubin J; Sideras K; Morris JC; McIver B; Burton JK; Webster KP; Bieber C; Traynor AM; Flynn PJ; Goh BC; Tang H; Ivy SP; Erlichman C; ; ;
    Lancet Oncol; 2010 Oct; 11(10):962-72. PubMed ID: 20851682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
    O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
    Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
    Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
    Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.
    Bible KC; Suman VJ; Menefee ME; Smallridge RC; Molina JR; Maples WJ; Karlin NJ; Traynor AM; Kumar P; Goh BC; Lim WT; Bossou AR; Isham CR; Webster KP; Kukla AK; Bieber C; Burton JK; Harris P; Erlichman C; ;
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3179-84. PubMed ID: 22774206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
    Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
    Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
    Taylor SK; Chia S; Dent S; Clemons M; Agulnik M; Grenci P; Wang L; Oza AM; Ivy P; Pritchard KI; Leighl NB
    Oncologist; 2010; 15(8):810-8. PubMed ID: 20682606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
    Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
    Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.
    Lim WT; Ng QS; Ivy P; Leong SS; Singh O; Chowbay B; Gao F; Thng CH; Goh BC; Tan DS; Koh TS; Toh CK; Tan EH
    Clin Cancer Res; 2011 Aug; 17(16):5481-9. PubMed ID: 21712450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.
    Campos SM; Brady WE; Moxley KM; O'Cearbhaill RE; Lee PS; DiSilvestro PA; Rotmensch J; Rose PG; Thaker PH; O'Malley DM; Hanjani P; Zuna RE; Hensley ML
    Gynecol Oncol; 2014 Jun; 133(3):537-41. PubMed ID: 24594074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
    Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
    Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
    Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
    Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapies for pheochromocytoma and paraganglioma.
    Jimenez C; Fazeli S; Román-Gonzalez A
    Endocr Relat Cancer; 2020 Jul; 27(7):R239-R254. PubMed ID: 32369773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
    Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
    Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
    Matrana MR; Duran C; Shetty A; Xiao L; Atkinson BJ; Corn P; Pagliaro LC; Millikan RE; Charnsangave C; Jonasch E; Tannir NM
    Eur J Cancer; 2013 Oct; 49(15):3169-75. PubMed ID: 23810246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
    Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
    Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.
    Ilanchezhian M; Jha A; Pacak K; Del Rivero J
    Curr Treat Options Oncol; 2020 Aug; 21(11):85. PubMed ID: 32862332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
    J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.